Simon Bonouvrie

A growth stock we are excited about is Xenith IP (XIP), which is a newly listed small-cap stock with a market cap of approximately $130 million. Xenith IP is an intellectual property firm specialising in the filing and prosecuting of patents and trademarks in Australia on behalf of both international... Show More

Simon Bonouvrie

Key factors for assessing how far and fast a company can grow include; examining both the organic and acquisition opportunities available to it and the attractiveness of the industry that the it operates i.e. is the industry-high growth and is the company in a position to exploit this opportunity now... Show More

Simon Bonouvrie

At Cadence, we have a process of scaling into and out of stock positions. When a price trend in a stock turns and moves materially off a previous high we will start selling the position. This process of scaling out of the position continues as the stock trends lower. We... Show More

Simon Bonouvrie

The market is pricing in a recession scenario for the Australian Banks. The sector is pricing in a ramp-up of bad debts over the next couple of years, however, we think the Australian economy is proving more resilient than many people think and the bad debt experience for the... Show More

Simon Bonouvrie

The single most important indicator of company health is Free Cash Flow, or Free Cash Flow Yield. This figure is the amount of cash profits generated by the business after taking into account maintenance and expansionary capex. Alternatively, it is the amount left over from profits that are available to... Show More

Simon Bonouvrie

Investors have a preference for stocks that are delivering earnings and dividend growth. Some stocks have been sold off aggressively where there has either been an earnings downgrade or there is uncertainty as to whether a company will meet current earnings expectations in the market. For some stocks it has... Show More

Simon Bonouvrie

I believe the market hasn’t fully factored in the negative effect of the falling Australian dollar on importing companies. Therefore sectors such as retail and distribution companies have the potential to surprise on the downside. The AUD has fallen 22% from USD94c to USD72.8c over the past twelve months and... Show More

Simon Bonouvrie

Gilead Sciences (NASDAQ: GILD) was the first offshore position in the Cadence portfolio, initiated in mid-2014. We initiated the position at a price of approx US$82 and have added to the stock since then. The stock is currently US$122. Gilead is a large US biotech stock specialising in antiviral drugs... Show More

No comments.